Acute promyelocytic leukemia other imaging studies

Revision as of 07:08, 13 May 2018 by Shyam Patel (talk | contribs)
Jump to navigation Jump to search

Acute promyelocytic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute promyelocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary PreventionSurgery

Secondary PreventionSurgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute promyelocytic leukemia other imaging studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute promyelocytic leukemia other imaging studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute promyelocytic leukemia other imaging studies

CDC on Acute promyelocytic leukemia other imaging studies

Acute promyelocytic leukemia other imaging studies in the news

Blogs on Acute promyelocytic leukemia other imaging studies

Directions to Hospitals Treating Acute promyelocytic leukemia

Risk calculators and risk factors for Acute promyelocytic leukemia other imaging studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Acute promyelocytic leukemia other imaging findings=

  • Echocardiogram: An echocardiogram is an essential imaging modality in acute promyelocytic leukemia. Patients who will be receiving anthracycline-based therapy require a baseline echocardiogram to assess the ejection fraction prior to therapy. Anthracyclines are known to cause cardiac toxicity (specifically cardiomyopathy with cumulative anthracycline doses above 500mg/m2). An echocardiogram should be obtained every three months while on therapy with anthracycline. Echocardiogram applies particularly to cases of high-risk acute promyelocytic leukemia, in which case the standard of care is to give anthracycline along with all-trans retinoic acid.

References

Template:WH Template:WS